Benchmark Company

In a report published Monday, Benchmark Company analyst James Terwilliger reiterated a Hold rating and $17.00 price target on Vascular Solutions (NASDAQ: VASC). In the report, Terwilliger noted, “After the close of business on Friday, March 15, 2013, VASC announced that the company has initiated a...

In a report published Monday, Benchmark Company analyst James Terwilliger reiterated a Buy rating and $69.00 price target on ICU Medical (NASDAQ: ICUI). In the report, Terwilliger noted, “We were recently marketing with a member of the ICU Medical management team, and we remain comfortable with...

In a report published Monday, Benchmark Company analyst Raymond Myers terminated the firm's coverage of BioClinica (NASDAQ: BIOC). In the report, Myers noted, “BioClinica announced it has completed its previously disclosed agreement with the private equity firm, JLL Partners, to acquire BioClinica...

In a report published Friday, Benchmark Company analyst Edward J. Atorino reiterated his Buy rating on Nielsen Holdings (NYSE: NLSN), and raised his price target from $36.00 to $38.00. In the report, Atorino noted, “On March 8, AC Nielsen (NLSN-Buy, PT from $36 to $38) announced that it had...

In a report published Friday, Benchmark Company analyst Edward J. Atorino reiterated his Buy rating on Moody's Corporation (NYSE: MCO), and raised the price target from $52.00 to $60.00. In the report, Atorino noted, “Moody's (MCO-Buy) share price has rebounded 15% since mid-February following a...

In a report published Friday, Benchmark Company analyst James Terwilliger reiterated his Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII), and raised his price target from $18.00 to $24.00. In the report, Terwilliger noted, “We are publishing our fiscal 2014 revenue and EPS...

In a report published Monday, Benchmark Company reiterated its Buy rating and $17.00 price target on Perion Network Ltd. (NASDAQ: PERI). Benchmark Company noted, “Perion (PERI-Buy, PT $17) is set to report 4Q12 results on March 13 before the market open. The shares have been under pressure for...

In a report published Friday, Benchmark Company reiterated its Buy rating on Zillow (NASDAQ: Z), and raised its price target from $40.00 to $60.00. Benchmark Company noted, “February user traffic, released yesterday, was viewed as disappointing by the street given the modest q/q decline in the...

In a report published Friday, Benchmark Company reiterated its Buy rating and $87.00 price target on Analogic Corporation (NASDAQ: ALOG). Benchmark Company noted, “ALOG announced that the company completed the Ultrasonix Medical acquisition. Ultrasonix Medical is a supplier of advanced ultrasound...

In a report published Wednesday, Benchmark Company reiterated its Buy rating and $13.00 price target on Smith & Wesson Holding Corporation (NASDAQ: SWHC). Benchmark Company noted, “Smith & Wesson reported a strong Q3FY13 (January-end), with sales and EPS from continuing operations of $136...

In a report published Wednesday, Benchmark Company reiterated its Buy rating and $5.50 price target on 1-800-FLOWERS.com (NASDAQ: FLWS). Benchmark Company noted, “We recently hosted 1-800-flowers.com management in Boston. While shares have appreciated following several consecutive quarters of...

In a report published Wednesday, Benchmark Company reiterated its Buy rating on AeroVironment (NASDAQ: AVAV), but lowered its price target from $38.00 to $24.00. Benchmark noted, “AV reported a significantly weaker than expected Q3 and lowered guidance. Sales and EPS were $471 million and $0.17 vs...

In a report published Friday, Benchmark Company reiterated its Buy rating on LIN Television Corporation (NYSE: TVL), and raised its price target from $8.00 to $14.00. Benchmark Company noted, “Lin TV (TVL-Buy, PT from $8 to $14) reported 4Q12 revenues of $196 million, up 76% y/y, slightly above...

In a report published Friday, Benchmark Company reiterated its Buy rating on Bio-Reference Laboratories (NASDAQ: BRLI), and raised its price target from $32.00 to $36.00. Benchmark Company noted, “We are increasingly confident in BRLI's organic earnings growth trend. Adjusted for $0.03 estimated...

In a report published Monday, Benchmark Company reiterated its Buy rating and $33.00 price target on Progress Software Corporation (NASDAQ: PRGS). Benchmark Company noted, “We recently met with Progress Software's Chief Financial Officer (CFO) Chris Perkins, who replaced former CFO Melissa Cruz in...